Clinical disclaimer: This article is for informational purposes only and does not constitute medical advice. Never start, stop, or change medication without clinical supervision.

Key Points

  • SURPASS-CVOT showed tirzepatide was noninferior to dulaglutide for cardiovascular outcomes in type 2 diabetes
  • Primary event rate: 12.2% with tirzepatide versus 13.1% with dulaglutide — hazard ratio 0.92
  • This is noninferiority against an established outcomes drug — not a dramatic superiority headline
  • Proving you are not worse than an established outcomes drug is still clinically meaningful
  • SURPASS-CVOT strengthens tirzepatide's credibility without ending every comparative cardiovascular argument

SURPASS-CVOT mattered because tirzepatide had already captured the metabolic imagination. The next serious question was whether it would prove itself on cardiovascular outcomes. A primary event occurred in 12.2% of patients assigned tirzepatide and 13.1% of those assigned dulaglutide, giving a hazard ratio of 0.92. [1]

What the trial showed

That result requires careful reading. The trial showed noninferiority to dulaglutide, a drug that already had cardiovascular outcome credibility. That is not the same thing as a dramatic superiority narrative. [1,2]

Why does the trial still matter? Because proving you are not worse than an established outcomes drug — while carrying tirzepatide's broader metabolic and weight-loss profile — is not trivial. It helps move tirzepatide into the realm of full-spectrum metabolic medicine. [1]

What most articles miss

Some articles underplay the result because it was not a dramatic superiority headline. Others oversell it. The more mature reading is that SURPASS-CVOT strengthens tirzepatide's credibility without ending every comparative cardiovascular argument. That is a more intellectually honest position.

A trial can matter greatly even when the headline is more nuanced than the market hoped. That is exactly the kind of judgment-led interpretation patients rarely receive.

Bottom line

SURPASS-CVOT did not deliver simplistic triumph. It delivered something more subtle and still important: tirzepatide held its ground against an established cardiovascular-outcomes drug while bringing its broader metabolic strengths with it. [1]

FAQ

Did SURPASS-CVOT show tirzepatide was superior to dulaglutide?
The key result supported noninferiority, not superiority. [1]
Why does that still matter?
Because dulaglutide already had cardiovascular outcome credibility, so matching it while offering other metabolic advantages is still important. [1]
What was the event rate?
A primary event occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group. [1]
Does SURPASS-CVOT settle all cardiovascular questions about tirzepatide?
No. It materially strengthens the case, but interpretation still requires context. [1,2]
Why is this relevant to patients?
Because many will hear that tirzepatide is 'stronger' without understanding which outcomes that claim does, and does not, properly cover.

References

  1. Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393:2409-2420. nejm.org
  2. Mounjaro (tirzepatide) prescribing information. FDA. 2026.